본문 바로가기
KERD
논문KCI 등재

Renal effects of uric acid: hyperuricemia and hypouricemia

Jong-Ho Lee|Jung Hwan Park|Young-Il Jo
대한내과학회 (The Korean Association Of Internal Medicine)|2020.11|The Korean Journal of Internal Medicine|제35권 제6호|pp. 1291-1304|DOI https://doi.org/10.3904/kjim.2020.410

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

Uric acidKidneyHyperuricemiaHypouricemia
주제분류내과학

초록

The prevalence of chronic kidney disease (CKD) is increasing worldwide. Although hyperuricemia has been associated with CKD in many studies, it remains controversial whether this is the cause or the result of decreased renal function. Recent observational studies of healthy populations and patients with CKD have reported that uric acid (UA) has an independent role in the development or progression of CKD. Experimental studies have shown several potential mechanisms by which hyperuricemia may cause or promote CKD. However, other reports have indicated an association between hypouricemia and CKD. This opposing effect is hypothesized to occur because UA is a major antioxidant in human plasma and is associated with oxidative stress. In this article, we discuss the potential association between UA imbalance and CKD and how they can be treated.

Abstract

The prevalence of chronic kidney disease (CKD) is increasing worldwide. Although hyperuricemia has been associated with CKD in many studies, it remains controversial whether this is the cause or the result of decreased renal function. Recent observational studies of healthy populations and patients with CKD have reported that uric acid (UA) has an independent role in the development or progression of CKD. Experimental studies have shown several potential mechanisms by which hyperuricemia may cause or promote CKD. However, other reports have indicated an association between hypouricemia and CKD. This opposing effect is hypothesized to occur because UA is a major antioxidant in human plasma and is associated with oxidative stress. In this article, we discuss the potential association between UA imbalance and CKD and how they can be treated.

참고문헌 (145)

  1. Eunhee Ji, "Prevalence of chronic kidney disease defined by using CKD-EPI equation and albumin-to-creatinine ratio in the Korean adult population", The Korean Journal of Internal Medicine, 31(6), pp.1120~1130 (2016), 대한내과학회[DOI]
  2. 진동찬, "Current characteristics of dialysis therapy in Korea: 2016 registry data focusing on diabetic patients", Kidney Research and Clinical Practice, 37(1), pp.20~29 (2018), 대한신장학회
  3. Levey AS, "Chronic kidney disease as a global public health problem : approaches and initiatives : a position statement from Kidney Disease Improving Global Outcomes", Kidney Int, 72, pp.247~259 (2007)
  4. Mahomed FA, "On chronic Bright’s disease, and its essential symptoms", Lancet, 1, pp.399~401 (1879)
  5. Haig A, "On uric acid and arterial tension", Br Med J, 1, pp.288~291 (1889)
  6. Davis NS, "The cardio-vascular and renal relations and manifestations of gout", J Am Med Assoc, 29, pp.261~262 (1897)
  7. Brochner-Mortensen K, "100 Gouty patients", Acta Med Scand, 106, pp.81~107 (1941)
  8. Talbott JH, "The kidney in gout", Medicine(Baltimore), 39, pp.405~467 (1960)
  9. Kang DH, "Uric acid and chronic kidney disease : new understanding of an old problem", Semin Nephrol, 31, pp.447~452 (2011)
  10. Johnson RJ, "Uric acid and chronic kidney disease : which is chasing which", Nephrol Dial Transplant, 28, pp.2221~2228 (2013)
  11. Wakasugi M, "Association between hypouricemia and reduced kidney function : a cross-sectional population-based study in Japan", Am J Nephrol, 41, pp.138~146 (2015)
  12. Wang S, "Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan", Nephrology(Carlton), 16, pp.767~776 (2011)
  13. Fathallah-Shaykh SA, "Uric acid and the kidney", Pediatr Nephrol, 29, pp.999~1008 (2014)
  14. Maiuolo J, "Regulation of uric acid metabolism and excretion", Int J Cardiol, 213, pp.8~14 (2016)
  15. Wu XW, "Two independent mutational events in the loss of urate oxidase during hominoid evolution", J Mol Evol, 34, pp.78~84 (1992)
  16. Desideri G, "Is it time to revise the normal range of serum uric acid levels", Eur Rev Med Pharmacol Sci, 18, pp.1295~1306 (2014)
  17. Oda M, "Loss of urate oxidase activity in hominoids and its evolutionary implications", Mol Biol Evol, 19, pp.640~653 (2002)
  18. Bobulescu IA, "Renal transport of uric acid : evolving concepts and uncertainties", Adv Chronic Kidney Dis, 19, pp.358~371 (2012)
  19. Hediger MA, "Molecular physiology of urate transport", Physiology(Bethesda), 20, pp.125~133 (2005)
  20. Preitner F, "Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy", Proc Natl Acad Sci U S A, 106, pp.15501~15506 (2009)
  21. Woodward OM, "Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout", Proc Natl Acad Sci U S A, 106, pp.10338~10342 (2009)
  22. Iharada M, "Type 1 sodium-dependent phosphate transporter(SLC17A1 Protein)is a Cl(-)-dependent urate exporter", J Biol Chem, 285, pp.26107~26113 (2010)
  23. Jutabha P, "Human sodium phosphate transporter 4(hNPT4", SLC17A3)as a common renal secretory pathway for drugs and urate, 2010, pp.285, 35123~35132
  24. Ichida K, "Decreased extra-renal urate excretion is a common cause of hyperuricemia", Nat Commun, 3, pp.764~ (2012)
  25. Nagura M, "Uric acid metabolism of kidney and intestine in a rat model of chronic kidney disease", Nucleosides Nucleotides Nucleic Acids, 35, pp.550~558 (2016)
  26. Yano H, "Uric acid transporter ABCG2 is increased in the intestine of the 5", 6 nephrectomy rat model of chronic kidney disease, 2014, pp.18, 50~55
  27. Zhu Y, "Prevalence of gout and hyperuricemia in the US general population : the National Health and Nutrition Examination Survey 2007-2008", Arthritis Rheum, 63, pp.3136~3141 (2011)
  28. Lin KC, "Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen", J Rheumatol, 27, pp.1045~1050 (2000)
  29. Abbasian M, "Association between serum uric acid(SUA)levels and metabolic syndrome(MetS)components in personnel of Shahroud University of Medical Sciences", Diabetes Metab Syndr, 10, pp.132~136 (2016)
  30. Quinones Galvan A, "Effect of insulin on uric acid excretion in humans", Am J Physiol, 268(1 Pt 1), pp.E1~E5 (1995)
  31. Messerli FH, "Serum uric acid in essential hypertension : an indicator of renal vascular involvement", Ann Intern Med, 93, pp.817~821 (1980)
  32. Johnson RJ, "Hypothesis : could excessive fructose intake and uric acid cause type 2diabetes", Endocr Rev, 30, pp.96~116 (2009)
  33. Han T, "Temporal relationship between hyperuricemia and insulin resistance and its impact on future risk of hypertension", Hypertension, 70, pp.703~711 (2017)
  34. Choi HK, "Purine-rich foods, dairy and protein intake, and the risk of gout in men", N Engl J Med, 350, pp.1093~1103 (2004)
  35. Franco MC, "Effects of low birth weight in 8-to 13-year-old children : implications in endothelial function and uric acid levels", Hypertension, 48, pp.45~50 (2006)
  36. Hummel A, "Familial juvenile hyperuricemic nephropathy", Nephrol Ther, 8, pp.117~125 (2012)
  37. Liu Y, "Tamm-Horsfall protein", uromodulin deficiency elicits tubular compensatory responses leading to hypertension and hyperuricemia, 2018, pp.314, F1062~F1076
  38. Olinger E, "Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease due to mutations in UMOD and MUC1", Kidney Int, 98, pp.717~731 (2020)
  39. Nakayama A, "GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes", Ann Rheum Dis, 76, pp.869~877 (2017)
  40. Ramsdell CM, "The clinical significance of hypouricemia", Ann Intern Med, 78, pp.239~242 (1973)
  41. Chang-Nam Son, "Prevalence and possible causes of hypouricemia at a tertiary care hospital", The Korean Journal of Internal Medicine, 31(5), pp.971~976 (2016), 대한내과학회[DOI]
  42. Sebesta I, "Hereditary xanthinuria is not so rare disorder of purine metabolism", Nucleosides Nucleotides Nucleic Acids, 37, pp.324~328 (2018)
  43. McDonagh EM, "PharmGKB summary : uric acid-lowering drugs pathway, pharmacodynamics", Pharmacogenet Genomics, 24, pp.464~476 (2014)
  44. Guttmann A, "Pegloticase in gout treatment : safety issues, latest evidence and clinical considerations", Ther Adv Drug Saf, 8, pp.379~388 (2017)
  45. Daskalopoulou SS, "Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia", Curr Pharm Des, 11, pp.4161~4175 (2005)
  46. Hamada T, "Uricosuric action of losartan via the inhibition of urate transporter 1(URAT 1)in hypertensive patients", Am J Hypertens, 21, pp.1157~1162 (2008)
  47. Uetake D, "Effect of fenofibrate on uric acid metabolism and urate transporter 1", Intern Med, 49, pp.89~94 (2010)
  48. Liberopoulos E, "Co-trimoxazole-induced hypouricemia", Clin Nephrol, 49, pp.202~ (1998)
  49. Ichida K, "Clinical and molecular analysis of patients with renal hypouricemia in Japan : influence of URAT1 gene on urinary urate excretion", J Am Soc Nephrol, 15, pp.164~173 (2004)
  50. Komoda F, "The W258X mutation in SLC22A12 is the predominant cause of Japanese renal hypouricemia", Pediatr Nephrol, 19, pp.728~733 (2004)
  51. Ichida K, "Age and origin of the G774A mutation in SLC22A12 causing renal hypouricemia in Japanese", Clin Genet, 74, pp.243~251 (2008)
  52. Cheong HI, "Mutational analysis of idiopathic renal hypouricemia in Korea", Pediatr Nephrol, 20, pp.886~890 (2005)
  53. Li Z, "Novel URAT1 mutations caused acute renal failure after exercise in two Chinese families with renal hypouricemia", Gene, 512, pp.97~101 (2013)
  54. Matsuo H, "Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia", Am J Hum Genet, 83, pp.744~751 (2008)
  55. Dinour D, "Homozygous SLC2A9 mutations cause severe renal hypouricemia", J Am Soc Nephrol, 21, pp.64~72 (2010)
  56. Sebesta I, "Genetic disorders resulting in hyper-or hypouricemia", Adv Chronic Kidney Dis, 19, pp.398~403 (2012)
  57. De Coek NM, "Serum urate and urate clearance in diabetes mellitus", Australas Ann Med, 14, pp.205~209 (1965)
  58. Herman JB, "Hyperglycemia and uric acid", Isr J Med Sci, 5, pp.1048~1052 (1969)
  59. Shichiri M, "Diabetic renal hypouricemia", Arch Intern Med, 147, pp.225~228 (1987)
  60. Erdberg A, "Urine uric acid excretion in patients with insulin-dependent diabetes mellitus", Nephron, 60, pp.134~137 (1992)
  61. Esparza Martin N, "Hypouricemia and tubular transport of uric acid", Nefrologia, 31, pp.44~50 (2011)
  62. Magoula I, "Cholangiocarcinoma and severe renal hypouricemia : a study of the renal mechanisms", Am J Kidney Dis, 18, pp.514~519 (1991)
  63. Izumi N, "Hypouricemia and renal tubular acidosis in primary biliary cirrhosis", Gastroenterol Jpn, 20, pp.374~379 (1985)
  64. Hisatome I, "Hypouricaemia with acute viral hepatitis", Br J Rheumatol, 28, pp.525~527 (1989)
  65. Tykarski A, "Mechanism of hypouricemia in Hodgkin’s disease. Isolated defect in postsecretory reabsorption of uric acid", Nephron, 50, pp.217~219 (1988)
  66. Mallat SG, "Hyperuricemia, hypertension, and chronic kidney disease : an emerging association", Curr Hypertens Rep, 18, pp.74~ (2016)
  67. Mazzali M, "Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism", Hypertension, 38, pp.1101~1106 (2001)
  68. Mazzali M, "Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism", Am J Physiol Renal Physiol, 282, pp.F991~F997 (2002)
  69. Sanchez-Lozada LG, "Mild hyperuricemia induces glomerular hypertension in normal rats", Am J Physiol Renal Physiol, 283, pp.F1105~F1110 (2002)[DOI]
  70. Kang DH, "A role for uric acid in the progression of renal disease", J Am Soc Nephrol, 13, pp.2888~2897 (2002)
  71. Sanchez-Lozada LG, "Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats", Kidney Int, 67, pp.237~247 (2005)
  72. Sanchez-Lozada LG, "Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations", Nephron Exp Nephrol, 121, pp.e71~e78 (2012)
  73. Khosla UM, "Hyperuricemia induces endothelial dysfunction", Kidney Int, 67, pp.1739~1742 (2005)
  74. Farquharson CA, "Allopurinol improves endothelial dysfunction in chronic heart failure", Circulation, 106, pp.221~226 (2002)
  75. Butler R, "Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension", Hypertension, 35, pp.746~751 (2000)
  76. Nakagawa T, "Hyperuricemia causes glomerular hypertrophy in the rat", Am J Nephrol, 23, pp.2~7 (2003)
  77. Ryu ES, "Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease", Am J Physiol Renal Physiol, 304, pp.F471~F480 (2013)
  78. Ames BN, "Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer : a hypothesis", Proc Natl Acad Sci U S A, 78, pp.6858~6862 (1981)
  79. Davies KJ, "Uric acid-iron ion complexes : a new aspect of the antioxidant functions of uric acid", Biochem J, 235, pp.747~754 (1986)
  80. Simic MG, "Antioxidation mechanisms of uric acid", J Am Chem Soc, 111, pp.5778~5782 (1989)
  81. Ostendorf BN, "Association between low uric acid levels and acute graftversus-host disease", Ann Hematol, 94, pp.139~144 (2015)
  82. Fang P, "A double-edged sword : uric acid and neurological disorders", Brain Disord Ther, 2, pp.109~ (2013)
  83. Ishikawa I, "Acute renal failure with severe loin pain and patchy renal ischemia after anaerobic exercise in patients with or without renal hypouricemia", Nephron, 91, pp.559~570 (2002)
  84. Kikuchi Y, "Patients with renal hypouricemia with exercise-induced acute renal failure and chronic renal dysfunction", Clin Nephrol, 53, pp.467~472 (2000)
  85. Ohta T, "Exercise-induced acute renal failure associated with renal hypouricaemia : results of a questionnaire-based survey in Japan", Nephrol Dial Transplant, 19, pp.1447~1453 (2004)
  86. Coca SG, "Chronic kidney disease after acute kidney injury : a systematic review and meta-analysis", Kidney Int, 81, pp.442~448 (2012)
  87. Bordier L, "Hypouricemia, an old subject and new concepts", Presse Med, 33, pp.555~563 (2004)
  88. Rosolowsky ET, "High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1diabetes", Clin J Am Soc Nephrol, 3, pp.706~713 (2008)
  89. Zoppini G, "Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function", Diabetes Care, 35, pp.99~104 (2012)
  90. Domrongkitchaiporn S, "Risk factors for development of decreased kidney function in a southeast Asian population : a 12-year cohort study", J Am Soc Nephrol, 16, pp.791~799 (2005)
  91. Chonchol M, "Relationship of uric acid with progression of kidney disease", Am J Kidney Dis, 50, pp.239~247 (2007)
  92. Obermayr RP, "Elevated uric acid increases the risk for kidney disease", J Am Soc Nephrol, 19, pp.2407~2413 (2008)
  93. Hsu CY, "Risk factors for end-stage renal disease : 25-year follow-up", Arch Intern Med, 169, pp.342~350 (2009)
  94. Bellomo G, "Association of uric acid with change in kidney function in healthy normotensive individuals", Am J Kidney Dis, 56, pp.264~272 (2010)
  95. Sonoda H, "Uric acid levels predict future development of chronic kidney disease", Am J Nephrol, 33, pp.352~357 (2011)
  96. Uchida S, "Targeting uric acid and the inhibition of progression to end-stage renal disease : a propensity score analysis", PLoS One, 10, pp.e0145506~ (2015)
  97. Rodenbach KE, "Hyperuricemia and progression of CKD in children and adolescents : the Chronic Kidney Disease in Children(CKiD)cohort study", Am J Kidney Dis, 66, pp.984~992 (2015)
  98. Oh TR, "Hyperuricemia has increased the risk of progression of chronic kidney disease : propensity score matching analysis from the KNOWCKD study", Sci Rep, 9, pp.6681~ (2019)
  99. Iseki K, "Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort", Am J Kidney Dis, 44, pp.642~650 (2004)
  100. Li L, "Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies", BMC Nephrol, 15, pp.122~ (2014)
  101. Chien KL, "A prediction model for the risk of incident chronic kidney disease", Am J Med, 123, pp.836~846 (2010)
  102. 이창현, "Framingham risk score and risk of incident chronic kidney disease: A community-based prospective cohort study", Kidney Research and Clinical Practice, 38(1), pp.49~59 (2019), 대한신장학회[DOI]
  103. Jhee JH, "High muscle-to-fat ratio is associated with lower risk of chronic kidney disease development", J Cachexia Sarcopenia Muscle, 11, pp.726~734 (2020)
  104. 김좌경, "Impact of sarcopenia on long-term mortality and cardiovascular events in patients undergoing hemodialysis", The Korean Journal of Internal Medicine, 34(3), pp.599~607 (2019), 대한내과학회[DOI]
  105. Lamacchia O, "Para-and perirenal fat thickness is an independent predictor of chronic kidney disease, increased renal resistance index and hyperuricaemia in type-2 diabetic patients", Nephrol Dial Transplant, 26, pp.892~898 (2011)
  106. 김예니, "Can management of the components of metabolic syndrome modify the course of chronic kidney disease?", Kidney Research and Clinical Practice, 39(2), pp.118~120 (2020), 대한신장학회[DOI]
  107. Sturm G, "Uric acid as a risk factor for progression of non-diabetic chronic kidney disease?: the Mild to Moderate Kidney Disease (MMKD) study", Exp Gerontol, 43, pp.347~352 (2008)
  108. Madero M, "Uric acid and longterm outcomes in CKD", Am J Kidney Dis, 53, pp.796~803 (2009)
  109. Srivastava A, "Uric acid and the risks of kidney failure and death in individuals with CKD", Am J Kidney Dis, 71, pp.362~370 (2018)
  110. Odden MC, "Uric acid levels, kidney function, and cardiovascular mortality in US adults : National Health and Nutrition Examination Survey(NHANES)1988-1994 and 1999-2002", Am J Kidney Dis, 64, pp.550~557 (2014)
  111. Tseng WC, "U-shaped association between serum uric acid levels with cardiovascular and all-cause mortality in the elderly : the role of malnourishment", J Am Heart Assoc, 7, pp.e007523~ (2018)
  112. Kanda E, "Uric acid level has a U-shaped association with loss of kidney function in healthy people : a prospective cohort study", PLoS One, 10, pp.e0118031~ (2015)
  113. Kuwabara M, "Prevalence and complications of hypouricemia in a general population : a large-scale cross-sectional study in Japan", PLoS One, 12, pp.e0176055~ (2017)
  114. 문광호, "Effect of Uric Acid on the Development of Chronic Kidney Disease: The Korean Multi-Rural Communities Cohort Study", 예방의학회지, 51(5), pp.248~256 (2018), 대한예방의학회
  115. 진동찬, "Analysis of mortality risk from Korean hemodialysis registry data 2017", Kidney Research and Clinical Practice, 38(2), pp.169~175 (2019), 대한신장학회[DOI]
  116. Liu X, "Effects of uric acid-lowering therapy on the progression of chronic kidney disease : a systematic review and meta-analysis", Ren Fail, 40, pp.289~297 (2018)
  117. Siu YP, "Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level", Am J Kidney Dis, 47, pp.51~59 (2006)
  118. Goicoechea M, "Effect of allopurinol in chronic kidney disease progression and cardiovascular risk", Clin J Am Soc Nephrol, 5, pp.1388~1393 (2010)
  119. Momeni A, "Effect of allopurinol in decreasing proteinuria in type 2diabetic patients", Iran J Kidney Dis, 4, pp.128~132 (2010)
  120. Shi Y, "Clinical outcome of hyperuricemia in IgA nephropathy : a retrospective cohort study and randomized controlled trial", Kidney Blood Press Res, 35, pp.153~160 (2012)
  121. Sircar D, "Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia : a 6-month, double-blind, randomized, placebo-controlled trial", Am J Kidney Dis, 66, pp.945~950 (2015)
  122. Kimura K, "Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia : a randomized trial", Am J Kidney Dis, 72, pp.798~810 (2018)
  123. Lee JW, "Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease", Int Urol Nephrol, 51, pp.467~473 (2019)
  124. Zhang X, "Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia", Int Urol Nephrol, 51, pp.2273~2283 (2019)
  125. Hande KR, "Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency", Am J Med, 76, pp.47~56 (1984)
  126. Khanna D, "American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia", Arthritis Care Res(Hoboken), 64, pp.1431~1446 (2012)
  127. Stamp LK, "Starting dose is a risk factor for allopurinol hypersensitivity syndrome : a proposed safe starting dose of allopurinol", Arthritis Rheum, 64, pp.2529~2236 (2012)
  128. Wallace SL, "Therapy in gout", Rheum Dis Clin North Am, 14, pp.441~457 (1988)
  129. Halevy S, "Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel", J Am Acad Dermatol, 58, pp.25~32 (2008)
  130. Kanbay M, "Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions", Int Urol Nephrol, 39, pp.1227~1233 (2007)
  131. Mittal M, "Reactive oxygen species in inflammation and tissue injury", Antioxid Redox Signal, 20, pp.1126~1167 (2014)
  132. Schlesinger N, "Beyond urate lowering : analgesic and anti-inflammatory properties of allopurinol", Semin Arthritis Rheum, 50, pp.444~450 (2020)
  133. Doehner W, "Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure : results from 2 placebo-controlled studies", Circulation, 105, pp.2619~2624 (2002)
  134. Khan F, "Allopurinol treatment reduces arterial wave reflection in stroke survivors", Cardiovasc Ther, 26, pp.247~252 (2008)
  135. George J, "The role of urate and xanthine oxidase inhibitors in cardiovascular disease", Cardiovasc Ther, 26, pp.59~64 (2008)
  136. Mercuro G, "Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk", Am J Cardiol, 94, pp.932~935 (2004)
  137. Shibagaki Y, "Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction", Hypertens Res, 37, pp.919~925 (2014)
  138. Sang-Hyon Kim, "Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4–5 chronic kidney disease not yet on dialysis", The Korean Journal of Internal Medicine, 35(4), pp.998~1003 (2020), 대한내과학회[DOI]
  139. Avena-Woods C, "Febuxostat (Uloric), a new treatment option for gout", Pharmacy and Ther, 35, pp.82~ (2010)
  140. White WB, "Cardiovascular safety of febuxostat or allopurinol in patients with gout", N Engl J Med, 378, pp.1200~1210 (2018)
  141. Ran-hui Cha, "Physicians’ perceptions of asymptomatic hyperuricemia in patients with chronic kidney disease: A questionnaire survey", Kidney Research and Clinical Practice, 38(3), pp.373~381 (2019), 대한신장학회[DOI]
  142. 신동호, "To treat or not to treat asymptomatic hyperuricemia in chronic kidney disease", Kidney Research and Clinical Practice, 38(3), pp.257~259 (2019), 대한신장학회[DOI]
  143. Chamorro A, "Safety and efficacy of uric acid in patients with acute stroke(URICO-ICTUS) : a randomised, double-blind phase 2b", 3 trial, 2014, pp.13, 453~460
  144. Llull L, "Uric acid therapy improves clinical outcome in women with acute ischemic stroke", Stroke, 46, pp.2162~2167 (2015)
  145. Perez-Gomez MV, "Potential dangers of serum urate-lowering therapy", Am J Med, 132, pp.457~467 (2019)

관련 논문AI추천

Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular diseaseDong Sun, Fan Yang, Yousuf Waheed대한내과학회 · The Korean Journal of Internal Medicine2021 · 제36권 제6호만성 콩팥병에서 고요산혈증은 왜 중요한가?김수현대한내과학회 · 대한내과학회지2025 · 제100권 제3호Effect of Uric Acid on the Development of Chronic Kidney Disease: The Korean Multi-Rural Communities Cohort Study김미경, 문광호, 신동훈, 신민호, 유경임, 최보열대한예방의학회 · 예방의학회지2018 · 제51권 제5호Association between serum uric acid and kidney disease with pediatric focusCho Myung Hyun대한소아신장학회 · Childhood Kidney Diseases2024 · 제28권 제3호Hyperuricemia and Urologic Disease민승기, 조인창대한요로생식기감염학회 · Urogenital Tract Infection2017 · 제12권 제3호Uric acid and cardiometabolic diseases성기철, 오병길, Lee Seung Jae대한고혈압학회 · Clinical Hypertension2020 · 제26권 제3호

이 간행물의 다른 논문 (30건)

Clinical characteristics of coronavirus disease 2019 patients with diarrhea in DaeguMin Cheol Kim, Kook Hyun Kim, Tae Nyeun Kim, Jung Gil Park, 장병익, 김경옥, Min Kyu Kang, Sung Bum Kim, Joon Hyun Cho, See Hyung Leepp. 1261-1269What should we prepare for the next coronavirus disease 2019 outbreak? A survey on the opinions of infectious diseases specialists in South KoreaThe Korean Society of Infectious Diseases, 김신우, 장현하, 정동식, 박세윤, Sook In Jung, Kyong Ran Peck, 오원섭, Bongyoung Kimpp. 1270-1278Nutritional management in patients with chronic kidney diseaseSun Moon Kim, Ji Yong Jungpp. 1279-1290The clinical impact of gut microbiota in chronic kidney diseaseIl Han Song, So Mi Kimpp. 1305-1316Recommendations for the management of patients with systemic rheumatic diseases during the coronavirus disease pandemic서미령, Hyun-Sook Kim, The Korean College of Rheumatology Working Group, 김건우, 엄중식, 정승민, 이지수, 김형진, 이명수, Ji-Won Kim, 허지안, Yoon-Kyoung Sung, Eun-Jung Park, Bum Sik Chin, 백한주pp. 1317-1332
원문 보기